Global X Robotics and Artificial Intelligence ETF vs GSK plc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.73, while GSK plc trades at $50.36 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while Global X Robotics and Artificial Intelligence ETF pays none. Which is the better fit depends on your goals.
| BOTZ | GSK | |
|---|---|---|
52-Week High | $41.63 | $61.18 |
52-Week Low | $31.99 | $38.22 |
Market Cap | — | $102.60B |
Sector | — | Health |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.81, up 1.04% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on robotics and AI, with news highlighting its role in the expanding automation theme. Key support and resistance cluster tightly around $37-$38, indicating a critical price zone.
Outlook remains positive due to structural growth in robotics and AI, though high RSI suggests near-term consolidation risk. Competition from other thematic ETFs and macroeconomic sensitivity are key risks for investors.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Trailing returns across standard periods
Latest headlines on both assets
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →